How AON Built an Outpatient BiTE Therapy Program for Multiple Myeloma

Bispecific T-cell engager therapies have become an important option for patients with relapsed or refractory multiple myeloma, particularly those who have received several prior lines of therapy. Because these agents can be administered as an off-the-shelf treatment, they may offer a practical advantage in the community oncology setting compared with CAR T-cell therapy, which often requires referral to a specialized treatment center and additional lead time before treatment can begin.